Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 2025. The quarter-end value of the position rose by $122.09 million, reflecting the new purchase.